Seeking Alpha

Cubist takes exception to generic threat

  • Fresenius Kabi USA sends Cubist Pharmaceuticals (CBST +0.1%) a letter notifying it that it has submitted an ANDA for a generic version of Cubicin (daptomycin for injection) which, according to Cubist, is protected by six Orange Book-listed patents expiring between 2016 and 2028. Fresenius alleges that five of the patents are invalid and unenforceable. Cubist intends to file a complaint with the FDA within 45 days. Once it files its lawsuit, the FDA will institute an automatic 30-month stay on its approval decision.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs